Notably, dual blockage of LAG‐3 (using relatlimab) and PD‐1 (using nivolumab) was shown to have effective synergism and higher clinical efficacy in a subset of melanoma patients with progressive disease who previously showed no durable response to anti‐PD‐1/PD‐L1 monotherapy.55 This evidence concerns the gene CD274 and melanoma.